Fractyl Health Q1 net loss $23.7M, cash $42.1M; REMAIN-1 pivotal enrollment complete

FRACTYL HEALTH, INC.

2025-Q1 EPS reported -$0.49

Net loss $23.7M vs $3.3M YoY, driven by non-cash fair value change and $3.2M operating expense increase.
Cash $42.1M expected to fund operations into Q4 2025; R&D expenses rose to $19.4M from $14.4M.
REMAIN-1 Pivotal Cohort (315 patients) enrollment completed ahead of schedule; 6-month primary endpoint data H2 2026.
REVEAL-1 3-month open-label data update expected June 2025; REMAIN-1 Midpoint Cohort data Q3 2025.
Rejuva gene therapy advancing; first CTA module submission for RJVA-001 expected June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.